Exopharm Limited has reached an agreement to conduct a research collaboration with Showa Denko Materials Co., Ltd. (SDMC). Under the Feasibility Study Agreement, SDMC will evaluate the LEAPTM technology platform within its regenerative medicine business unit at its Yokohama facility. This evaluation will allow Exopharm's patent-protected LEAP technology and know-how to be studied within SDMC's Yokohama facility and by its experts assisted by Exopharm. If the research project is successful there is potential for a further future commercial agreement. Showa Denko is an established international supplier of drug and other chemical substances. If this feasibility study is successful, exosomes purified using LEAP could be yet another valuable product in their portfolio," said Dr Chris Baldwin, Chief Commercial Officer of Exopharm. "This collaboration follows the work are doing with the Finnish Red Cross Blood Service. As the number of collaborations build, their confidence that LEAP could become the global standard for purifying exosome medicines continues to grow.